Table 2.
Outcome data relating to taurolidine vs controls
| Cohort number | Number of CRBSI | Number of catheter days | Rate of CRBSI per 1000 catheter days | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| First author | Control type | Taurolidine type | Control | Taurolidine | Control | Taurolidine | Control | Taurolidine | Control | Taurolidine | Rate ratio |
| Al‐Amin 3 | 2 | TC (2% T, 4% C) | 9 | 9* | ‐ | ‐ | ‐ | ‐ | 6.39 | 0 | 0 |
| Barnova 21 | 2 | TC | 28 | 28* | 142 | 18 | 20,881 | 19,642 | 6.8 | 0.92 | 0.14 |
| Bisseling 22 | 1 | T | 14 | 16 | 10 | 1 | 4939 | 5370 | 2.02 | 0.19 | 0.09 |
| Buang 23 | 2 | TC | 13 | 13* | ‐ | ‐ | ‐ | ‐ | 5.3 | 0.09 | 0.17 |
| Chong 24 | 1 | TC (2% T, 4% C) | 13 | 13* | 33 | 9 | 2946 | 4737 | 11.2 | 1.9 | 0.17 |
| Chu 25 | 1 | TC (2% T, 4% C) | 19 | 19* | 57 | 10 | 6630 | 9520 | 8.6 | 1.1 | 0.13 |
| Clark 26 | 1 | TC (1.35% T, 4% C) | 19 | 19* | 39 | 5 | 7077 | 10,359 | 5.5 | 0.5 | 0.09 |
| Cullis 27 | 2 | TC (2% T, 4% C) | 42 | 7 | 88 | 6 | 36,148 | 5480 | 2.43 | 1.09 | 0.44 |
| Cullis 27 | 2 | TC (2% T, 4% C) | 7 | 7* | 60 | 6 | 6737 | 5480 | 8.9 | 1.09 | 0.12 |
| German‐Diaz 28 | 2 | T | 8 | 5 | 17 | 5 | 3288 | 2055 | 2.39 | 0.93 | 0.09 |
| Hulshof 29 | 1 | T (2% T) | 7 | 7* | 59 | 14 | 4614 | 3262 | 12.7 | 4.3 | 0.34 |
| Hulshof 29 | 3 | T (2% T) | 16 | 16* | 41 | 8 | 2747 | 2598 | 14.9 | 3.1 | 0.21 |
| Jonkers 30 | 1 | T (2% T) | 32 | 32* | 17 | 4 | 11,680 | 11,680 | 1.46 | 0.34 | 0.24 |
| Jonkers 30 | 1 | T (2% T) | 8 | 8* | 4 | 1 | 2920 | 2920 | 1.37 | 0.34 | 0.25 |
| Jurewitsch 31 | 2 | T (2% T) | 7 | 7* | 35 | 8 | 3930 | 5500 | 8.9 | 1.47 | 0.17 |
| Klemesrud 32 | 1 + 5 | T (1.35% T) | 7 | 7* | 14 | 1 | 8383 | 4000 | 1.67 | 0.25 | 0.15 |
| Lambe 33 | 4 | TC (1.35% T, 4% C) | 86 | 40 | 89 | 5 | 99,774 | 20,403 | 0.89 | 0.25 | 0.28 |
| Lambe 33 | 4 | TC (1.35% T, 4% C) | 36 | 36* | 415 | 5 | 99,774 | 20,403 | 4.16 | 0.25 | 0.06 |
| Lau 34 | 3 | TC (2% T, 4% C) | 17 | 17* | 7 | 1 | 5955 | 1753 | 1.18 | 0.57 | 0.48 |
| Leiberman 35 | 1 | TCH (2% T, 100 IU/ml H, 4% C) | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | 2.36 | 0.3 | 0.13 |
| Lyszkowska 36 | 2 | TC (2% T, 4% C) | 49 CVCs | 48 CVCs | 14 | 1 | 976 | 942 | 14.3 | 1.06 | 0.07 |
| Merlo 37 | 2 | TC (4% C) | 23 | 23* | 28 | 0 | 16,790 | 8395 | 1.65 | 0 | 0 |
| Merras‐Salmio 38 | 3 | TCH | 100 | 100* | 56 | 24 | 38,888 | 38,095 | 1.44 | 0.63 | 0.44 |
| Nader 39 | 2 | TC (2% T, 4% C) | 25 | 25* | 66 | 3 | 12,775 | 12,775 | 5.2 | 0.2 | 0.04 |
| Nascimento 40 | 2 | TC (2% T, 4% C) | 11 | 11* | 13 | 1 | 2281 | 3333 | 5.7 | 0.3 | 0.05 |
| Novak 41 | 1 | T | 135 | ‐ | ‐ | ‐ | ‐ | ‐ | 1.9 | 1.09 | 0.57 |
| Olthof 42 | 1 | T (2% T) | 545 CVCs | 200 CVCs | 464 | 43 | 147,842 | 71,112 | 3.1 | 0.6 | 0.19 |
| Parmar 43 | 2 | TCH (2% T, 100 IU/ml H, 4% C) | ‐ | 10 | 26 | 11 | 5274 | 5473 | 4.93 | 2.01 | 0.41 |
| Rafferty 44 | 2 | TC (2% T, 4% C) | 16 | 16* | 94 | 29 | 9632 | 8912 | 9.8 | 3.3 | 0.34 |
| Rodriguez 45 | 4 | T (2% T) | 13 | 13* | 38 | 4 | 12,186 | 5293 | 3.12 | 0.76 | 0.24 |
| Saunders 46 | 4 | T | 22 | 22* | 42 | 12 | 7351 | 12,121 | 5.71 | 0.99 | 0.17 |
| Taniguchi 47 | 2 | TC (2% T, 4% C) | 6 | 6* | 28 | 4 | 3294 | 2500 | 8.5 | 1.6 | 0.19 |
| Toure 48 | 4 | TC (1.35% T, 4% C) | 15 | 15* | 36 | 6 | 5475 | 5475 | 6.58 | 1.09 | 0.17 |
| Tribler 49 | 1 | TCH (2% T, 100 IU/ml H, 4% C) | 20 | 21 | 7 | 0 | 6956 | 9622 | 1 | 0 | 0 |
| Waldenvik 50 | 2 | TC (2% T, 4% C) | 16 | ‐ | 17 | 0 | 2920 | 2920 | 5.93 | 0 | 0 |
| Witkowski 51 | 1 | TC (2% T, 4% C) | 14 | 14 | 10 | 4 | 3889 | 4371 | 2.6 | 0.9 | 0.35 |
| Wouters 52 | 4 | T (2% T) | 50 | 52 | 18 | 5 | 12,493 | 15,318 | 1.44 | 0.33 | 0.23 |
| Zamvar 53 | 2 | TC | 16 | 16* | 42 | 0 | 8371 | 4657 | 5.02 | 0 | 0 |
Note: Control types are as follows: 1 = heparin, 2 = standard care, 3 = antibiotic, 4 = saline, 5 = ethanol. Taurolidine types are as follows: C, H, and T. Hyphens in place of cell values denote insufficient data.
Abbreviations: C, citrate; CRBSI, catheter‐related bloodstream infection; CVC, central venous catheter; H, heparin; T, taurolidine.
*Pretest/posttest.